Systemic inflammatory factors in non-alcoholic steatohepatitis-induced hepatocellular carcinoma: A bidirectional Mendelian randomization analysis

被引:0
作者
Fu, Kang [1 ]
Zhou, Yiming [1 ]
Guo, Zhongyi [1 ]
Chen, Xiaotong [1 ]
Sun, Lin [2 ]
Hu, Xiao [1 ]
机构
[1] Qingdao Univ, Dept Hepatobiliary Pancreat Surg, Affiliated Hosp, Qingdao, Peoples R China
[2] Qingdao Univ, Dept ICU, Affiliated Hosp, Qingdao, Peoples R China
关键词
cirrhosis; inflammatory factors; Mendelian randomization; NAFLD; HCC; mediation analysis; FATTY LIVER-DISEASE; CIRRHOSIS; EPIDEMIOLOGY; PATHOGENESIS; HEPATITIS; NAFLD; RISK; NASH;
D O I
10.1177/1721727X241299494
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver condition globally, with its severe form, cirrhosis, leading to liver failure, hepatocellular carcinoma (HCC), and mortality. The causal relationships among them remain unclear. Methods: This study employed a two-sample Mendelian randomization (MR) approach to systematically investigate the causal relationships among inflammatory proteins, non-alcoholic steatohepatitis (NASH), and HCC. We utilized NASH data and HCC data from the FinnGen biobank, and genomic data for 91 circulating inflammatory factors from GWAS database. Bidirectional MR analyses were conducted using the Inverse-Variance Weighted method as the primary analysis, supplemented by MR-Egger and weighted median methods for sensitivity analyses. Additionally, we performed heterogeneity, pleiotropy, and MR-PRESSO tests to assess the robustness of our findings. Results: Forward MR analysis identified five inflammatory factors significantly associated with NASH risk: CCL25 (OR = 0.8703, p = .0159), S100A12 (OR = 0.7582, p = .0204), IL18 (OR = 0.7412, p = .0026), and LIFR (OR = 0.6804, p < .001) showed negative correlations, while CXCL11 (OR = 1.2625, p = .0354) demonstrated a positive correlation. Reverse analysis revealed that NASH significantly influenced the levels of 10 circulating inflammatory factors, including Beta-nerve growth factor (OR = 1.0286, p = .0245), CCL20 (OR = 1.0382, p = .0012), CD5 (OR = 1.0268, p = .0466), CUBD1 (OR = 1.0371, p = .0078), CSF1 (OR = 1.0231, p = .0458), IL-12 beta (OR = 1.0261, p = .0381), IL-22R alpha 1 (OR = 0.9722, p = .0311), CCL3 (OR = 1.0372, p = .0013), OPG (OR = 1.0436, p = .0103), and uPA (OR = 1.0320, p = .0054). Further analysis revealed that IL-1 alpha levels were positively associated with HCC risk (OR = 1.5335, p = .0377), while SULT1A1 levels showed a negative correlation (OR = 0.7190, p = .0200). Pleiotropy analyses showed no significant heterogeneity or horizontal pleiotropy for most identified associations, except for OPG (heterogeneity p = .001, MR-PRESSO p < .001) and CUBD1 (MR-PRESSO p < .05) in the reverse analysis of NASH, which warrant cautious interpretation. Conclusion: This study unveils complex bidirectional causal relationships among inflammatory factors, NASH, and HCC. Intervention targeting IL-1 alpha in patients with liver cirrhosis will significantly impact the progression of HCC.
引用
收藏
页数:11
相关论文
共 46 条
  • [31] Therapies with CCL25 require controlled release via microparticles to avoid strong inflammatory reactions
    Spinnen, J.
    Froehlich, K.
    Sinner, N.
    Stolk, M.
    Ringe, J.
    Shopperly, L.
    Sittinger, M.
    Dehne, T.
    Seifert, M.
    [J]. JOURNAL OF NANOBIOTECHNOLOGY, 2021, 19 (01)
  • [32] Interleukin 6 and liver regeneration
    Streetz, KL
    Luedde, T
    Manns, MP
    Trautwein, C
    [J]. GUT, 2000, 47 (02) : 309 - 312
  • [33] Interleukin 12 (IL-12) family cytokines: Role in immune pathogenesis and treatment of CNS autoimmune disease
    Sun, Lin
    He, Chang
    Nair, Lekha
    Yeung, Justine
    Egwuagu, Charles E.
    [J]. CYTOKINE, 2015, 75 (02) : 249 - 255
  • [34] Svensson Marcus, 2006, Expert Rev Clin Immunol, V2, P759, DOI 10.1586/1744666X.2.5.759
  • [35] CCR9 in cancer: oncogenic role and therapeutic targeting
    Tu, Zhenbo
    Xiao, Ruijing
    Xiong, Jie
    Tembo, Kingsley M.
    Deng, Xinzhou
    Xiong, Meng
    Liu, Pan
    Wang, Meng
    Zhang, Qiuping
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
  • [36] Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities
    Wen, Yankai
    Lambrecht, Joeri
    Ju, Cynthia
    Tacke, Frank
    [J]. CELLULAR & MOLECULAR IMMUNOLOGY, 2021, 18 (01) : 45 - 56
  • [37] From NAFLD to NASH to cirrhosis - new insights into disease mechanisms
    Wree, Alexander
    Broderick, Lori
    Canbay, Ali
    Hoffman, Hal M.
    Feldstein, Ariel E.
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2013, 10 (11) : 627 - 636
  • [38] The Roles of CCR9/CCL25 in Inflammation and Inflammation-Associated Diseases
    Wu, Xue
    Sun, Meng
    Yang, Zhi
    Lu, Chenxi
    Wang, Qiang
    Wang, Haiying
    Deng, Chao
    Liu, Yonglin
    Yang, Yang
    [J]. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [39] Interleukin-18-deficient mice develop dyslipidemia resulting in nonalcoholic fatty liver disease and steatohepatitis
    Yamanishi, Kyosuke
    Maeda, Seishi
    Kuwahara-Otani, Sachi
    Watanabe, Yuko
    Yoshida, Momoko
    Ikubo, Kaoru
    Okuzaki, Daisuke
    El-Darawish, Yosif
    Li, Wen
    Nakasho, Keiji
    Nojima, Hiroshi
    Yamanishi, Hiromichi
    Hayakawa, Tetsu
    Okamura, Haruki
    Matsunaga, Hisato
    [J]. TRANSLATIONAL RESEARCH, 2016, 173 : 101 - 114
  • [40] T cells, NK cells, and tumor-associated macrophages in cancer immunotherapy and the current state of the art of drug delivery systems
    Yang, Ya-long
    Yang, Fei
    Huang, Zhuan-qing
    Li, Yuan-yuan
    Shi, Hao-yuan
    Sun, Qi
    Ma, Yue
    Wang, Yao
    Zhang, Ying
    Yang, Sen
    Zhao, Guan-ren
    Xu, Feng-hua
    [J]. FRONTIERS IN IMMUNOLOGY, 2023, 14